Four insights:
1. Dr. Gomoll is an orthopedic surgeon specializing in sports medicine and principal investigator in the study.
2. The study’s goal is to compare the efficacy of the Agili-C cartilage regeneration implant to the current standard of care — microfracture and debridement.
3. Both patients had mild osteoarthritis, with one having an osteochondral defect and the other having two symptomatic lesions.
4. HSS is one of 15 sites participating in the study, which will involve 250 patients.
More articles on biologics:
Dr. Robert Brady: Robotics in spinal fusion and how the trend will develop in spine
Orthofix names DePuy, Medtronic, Biomet veteran the next CEO
Camber Spine delves into biologics with portfolio expansion
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.